You are here

Study: Millions Could Have Incorrect Statin, Aspirin and Blood Pressure Prescriptions

Newer data and statistical methods can improve diagnosis and prescribing

New research indicates that millions of Americans may need to talk to their doctor about taking different prescriptions of aspirin, statins, and blood pressure medications, according to a study led by Stanford researchers.

Sanjay Basu, MD, PhD, and his colleagues have come up with new calculations to help physicians decide whether to prescribe aspirin, blood pressure, or statin medications by estimating the risk a patient may have for a heart attack or stroke.

More than 11 million Americans may have incorrect prescriptions for aspirin, statins, and blood pressure medications, according to a study led by researchers at the Stanford University School of Medicine.

Their findings are based on an updated set of calculations—known as pooled cohort equations (PCEs)—that are used to determine the risk of a heart attack or stroke.

The PCEs are the foundation for cardiovascular disease prevention guidelines in the United States. They help physicians decide whether to prescribe aspirin, blood pressure, or statin medications, or some combination of these, by estimating the risk a patient may have for a heart attack or stroke. Most physicians calculate a patient’s risk using a PCE Web calculator or a smartphone app; the equations are also built into many electronic health records so that a patient’s risk is automatically calculated during an office visit.

But there has been debate over whether the PCEs are based on outdated data and therefore putting some patients at risk for over- or undermedication.

“We found that there are probably at least two major ways to improve the 2013 equations,” said Dr. Basu, Assistant Professor of Primary Care Outcomes Research at the Stanford School of Medicine and a core faculty member at Stanford Health Policy, in a statement. “The first was well-known: that the data used to derive the equations could be updated.”

For example, he said, one of the main data sets used to derive the original equations had information from people who were 30-62 years old in 1948, and who would therefore be 100 to 132 years old in 2018—that is, likely dead. The older equations were often estimating people’s risk as too high, possibly by an average of 20% across risk groups.

“A lot has changed in terms of diets, environments, and medical treatment since the 1940s,” Dr. Basu said. “So, relying on our grandparents’ data to make our treatment choices is probably not the best idea.”

Dr. Basu is the senior author of the study, which was published in the Annals of Internal Medicine. The lead author is Steve Yadlowsky, a graduate student in electrical engineering at Stanford.

Furthermore, the researchers found that the old data may not have had a sufficient sample of African-Americans. For many African-Americans, physicians may have been estimating the risks of heart attacks or strokes as too low.

“So while many Americans were being recommended aggressive treatments that they may not have needed according to current guidelines, some Americans—particularly African-Americans—may have been given false reassurance and probably need to start treatment given our findings,” Dr. Basu said.

For their study, the researchers updated the PCEs with newer data in an effort to substantially improve the accuracy of the cardiovascular risk estimates. A second improvement to the equations, the authors found, was to update the statistical methods used to derive the equations.

“We found that by revising the PCEs with new data and statistical methods, we could substantially improve the accuracy of cardiovascular disease risk estimates,” the authors wrote.

Researchers from the University of Michigan, University of Washington and University of Mississippi also contributed to the study.

Source: Stanford Medicine; June 4, 2018.

More Headlines

However, patent dispute will delay one launch
Some experts still opposed to “right to try” treatments
Approval acquired through tropical disease priority review voucher program
FDA questioning the pharmacokinetics of psoriasis lotion Duobrii
Therapy approved for adults and children with refractory PMBCL or who have relapsed after two or more prior lines of therapy
Latest failure brings amyloid hypothesis into question
Guidance published on how to best design coverage for treatment of the smallest, most vulnerable victims of the opioid crisis
Agency plans to respond after receipt of letter of concern
Continuous nerve stimulation helps to alleviate withdrawal symptoms